We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+4.14%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.13B
AUM Growth
+$291M
(+10%)
Cap. Flow
+$499M
Cap. Flow
% of AUM
15.92%
Top 10 Holdings %
Top 10 Hldgs %
65.45%
Holding
90
New
19
Increased
10
Reduced
3
Closed
13
Top Buys
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$159M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$94.1M |
| 3 |
Atea Pharmaceuticals
AVIR
|
+$83.8M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$61.6M |
| 5 |
TSVT
2seventy bio
TSVT
|
+$59.8M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$82.1M |
| 2 |
Shattuck Labs
STTK
|
+$75.6M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$25.2M |
| 4 |
Nurix Therapeutics
NRIX
|
+$24.8M |
| 5 |
BLUE
bluebird bio
BLUE
|
+$15.3M |
Sector Composition
| 1 | Healthcare | 99.03% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$450M
| $557M | 17.79% |
11,284,280
| – | – |
|
2
AnaptysBio
ANAB
$1.67B
| $261M | 8.34% |
7,521,024
| – | – |
|
3
Arcus Biosciences
RCUS
$3.51B
| $224M | 7.13% |
5,523,358
+400,999
| +8% | +$15.6M |
|
4
Xencor
XNCR
$1.1B
| $197M | 6.28% |
4,906,106
| – | – |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $191M | 6.09% |
+4,033,882
| New | +$159M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $187M | 5.97% |
3,951,566
| – | – |
|
|
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $123M | 3.91% |
2,224,403
+665,654
| +43% | +$34.7M |
|
8
Nuvation Bio
NUVB
$2.03B
| $118M | 3.77% |
13,896,543
+185,026
| +1% | +$1.7M |
|
9
Alector
ALEC
$164M
| $103M | 3.29% |
4,994,970
| – | – |
|
10
Protagonist Therapeutics
PTGX
$8.87B
| $90.3M | 2.88% |
2,639,706
+1,195,906
| +83% | +$37.8M |
|
|
11
CRISPR Therapeutics
CRSP
$4.99B
| $81.7M | 2.61% |
+1,077,483
| New | +$94.1M |
|
|
GRTS
12
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $77.3M | 2.47% |
6,012,232
+451,484
| +8% | +$5M |
|
|
13
Acadia Pharmaceuticals
ACAD
$4.45B
| $71.4M | 2.28% |
+3,060,593
| New | +$61.6M |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $65.6M | 2.09% |
2,759,505
| – | – |
|
|
ITOS
15
DELISTED
iTeos Therapeutics
ITOS
| $60.7M | 1.94% |
1,303,157
| – | – |
|
16
Relay Therapeutics
RLAY
$4.22B
| $54.6M | 1.74% |
1,779,084
+393,808
| +28% | +$12.4M |
|
17
Kura Oncology
KURA
$1B
| $52.1M | 1.66% |
3,724,437
| – | – |
|
18
Oric Pharmaceuticals
ORIC
$1.15B
| $51M | 1.63% |
3,468,944
| – | – |
|
|
TSVT
19
DELISTED
2seventy bio
TSVT
| $49.1M | 1.57% |
+1,917,063
| New | +$59.8M |
|
|
20
Atea Pharmaceuticals
AVIR
$385M
| $48.1M | 1.53% |
+5,376,134
| New | +$83.8M |
|
21
Design Therapeutics
DSGN
$838M
| $46.1M | 1.47% |
2,152,997
+289,899
| +16% | +$4.98M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $40M | 1.28% |
+940,636
| New | +$39.4M |
|
23
Janux Therapeutics
JANX
$971M
| $27.9M | 0.89% |
1,411,975
| – | – |
|
|
PRDS
24
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $26.1M | 0.83% |
1,597,139
+1,226,125
| +330% | +$14.3M |
|
|
VTYX
25
DELISTED
Ventyx Biosciences
VTYX
| $25.8M | 0.82% |
+1,300,000
| New | +$24.6M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM